Document:

EX-10.8

 Exhibit 10.8 
  

 
 19 October 2015 

André-Michel Ballester 

Dear André-Michel, 
 Proposed awards
under the LivaNova 2015 Incentive Award Plan (the “Plan”) 
 On behalf of LivaNova PLC (the “Company”), I can
confirm that after the Company’s shares (the “Shares”) are listed to trade on the London Stock Exchange and NASDAQ, but not later than 31 December 2015, we will request that the Compensation Committee recommends that the
following award(s) is/are made to you under the Plan: 
 2015 Award 

The Compensation Committee will be asked to recommend that an award of restricted stock units (“RSUs”) is made to you over
Shares equal in value to $5 million (the “2015 Award”). The calculation of the number of Shares subject to the 2015 Award will be determined based on the closing price of Shares on NASDAQ on the date of grant of the 2015 Award (the
“2015 Grant Date”). 
 The RSUs under the 2015 Award will vest as follows: 

 

	•	20% of the RSUs will vest on each of the first, second and third anniversaries of the 2015 Grant Date; and 

  

	•	the remaining 40% of the RSUs under the 2015 Award will vest on the fourth anniversary of the 2015 Grant Date. 

2016 Award 
 Not later than
31 December 2016, the Compensation Committee will be asked to recommend that the following awards are made to you under the Plan: 
  

	A.	2016 Restricted Stock Units 

 The Compensation Committee will be asked
to recommend that an award of RSUs is made to you over Shares equal in value to $3 million (the “2016 RSU Award”). The calculation of the number of Shares subject to the 2016 RSU Award will be determined based on the closing price
of Shares on NASDAQ on the date of grant of the 2016 RSU Award (the “2016 Grant Date”). 
 The RSUs under
the 2016 RSU Award will vest as follows: 
  

	 	1.	 One third of the RSUs under the 2016 RSU Award will be deemed “Net Sales RSUs” and these will vest if Group net sales revenue
targets for a relevant Financial Year (“FY”), as set by the Compensation Committee (the “Net Sales Targets”) have been exceeded. The Net Sales RSUs will vest in equal annual tranches of 25% of the total number of
Net Sales RSUs over the period of four years from grant, provided that a tranche of Net Sales RSUs in respect of a particular FY will only vest if, and to the extent that, the Net Sales Targets for that FY have been exceeded; 

  
 1 

	 	2.	 One third of the RSUs under the 2016 RSU Award will be deemed “Net Income RSUs” and these will vest if adjusted Group net income
targets for a relevant Financial Year (“FY”), as set by the Compensation Committee (the “Net Income Targets”) have been exceeded. The Net Income RSUs will vest in equal annual tranches of 25% of the total number of
Net Income RSUs over the period of four years from grant, provided that a tranche of Net Income RSUs in respect of a particular FY will only vest if, and to the extent that, the Net Income Targets for that FY have been exceeded; and

 If less than 100% of the shares vest in the first three years, you will be eligible to earn the
applicable portion of any shares that do not vest in the first three years if the Company achieves 100% of the applicable measure (Net Sales or Net Income) in the final year. 
  

	 	3.	 One third of the RSUs under the 2016 RSU Award will be deemed “Share Price RSUs” and these will vest during a specified period to
be determined by the Compensation Committee if the 50-day average closing price of Shares on NASDAQ during a specified period achieves a target which will be specified by the Compensation Committee. 

 

	B.	2016 Stock Options 

 The Compensation Committee will be asked to
recommend that an award of stock options is made to you over Shares equal in value to $1 million (the “2016 Option Award”). The calculation of the number of Shares subject to the 2016 Option Award will be determined based on the
Black-Scholes value calculated from the closing price of Shares on NASDAQ on the 2016 Grant Date. The exercise price per Share for the 2016 Option Award will be equal to the closing price of a Share on NASDAQ on the 2016 Grant Date. The 2016 Option
Award will vest in equal instalments over the period of four years from grant. 
 Future Awards 

You will be eligible to receive awards under the Plan for FY 2017 onwards, subject always to the discretion of the Compensation Committee.

 The grant of any of the awards under the Plan as described in this letter is of course always subject to the discretion of the
Compensation Committee and nothing in this letter shall be taken to fetter the discretion of the Compensation Committee. The Compensation Committee may decide not to grant awards as described in this letter. 

Vesting of any of the awards is conditional on your continued employment with the Company and vesting will cease upon you ceasing to be
employed by the Company. All awards made under the Plan will be subject to the terms of the Plan and the award agreement pursuant to which the particular award is granted. 

If you have any queries in relation to the terms of this letter, please do not hesitate to contact me. 

 

	
	 Kind regards

	
	 /s/ Daniel J. Moore

	
	Chairman

  
 2EX-10.1

 Exhibit 10.1 

CHANGE IN CONTROL SEVERANCE AGREEMENT 

This Change in Control Severance Agreement (the “Agreement”) is made as of October 13, 2015, by and between Cempra,
Inc., a Delaware corporation with its principal executive offices at 6320 Quadrangle Drive, Suite 360, Chapel Hill, NC 27517 (the “Company”), and David W. Oldach, M.D. (the “Employee”). 

W  I  T  N  E  S  S  E  T  H: 

WHEREAS, the Company presently employs Employee as its Chief Medical Officer; 

WHEREAS, the Company and Employee desire to set forth consideration to be paid to Employee if his employment is terminated under certain
circumstances following a “Change in Control” of the Company as defined herein; and 
 WHEREAS, the Company wishes to protect its
investment in its business, employees, customer relationships, and confidential information, by requiring Employee to abide by certain restrictive covenants regarding competition and other matters, each of which is an inducement to the Company to
provide Employee with the benefits described in this Agreement; 
 NOW, THEREFORE, in consideration of the foregoing, the mutual promises
herein contained, and other good and valuable consideration, including the continued employment of Employee by the Company and the compensation received by Employee from the Company from time to time, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 1. Definitions. For the purposes of the
Agreement, the following terms shall be defined as set out below: 
 (a) “Base Salary” shall mean Employee’s then
current annual base salary. 
 (b) “Board” means the Company’s Board of Directors. 

(c) “Effective Date” shall mean the date first written above. 

(d) A “Change In Control” shall be deemed to have occurred upon the consummation of (i) a merger or consolidation in
which the shareholders of the Company immediately prior to the merger or consolidation cease to own at least 50% of the combined entity immediately following the merger or consolidation; (ii) a sale of all or substantially all of the assets of
the Company; (iii) the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of beneficial ownership of any capital stock of the Company, if,
after such acquisition, such individual, entity or group owns more than 50% of either (A) the then-outstanding common stock of the Company or (B) the combined voting power of the then-outstanding securities of the Company entitled to vote
in the election of directors; or (iv) the liquidation or dissolution of the Company. 

 (e) “Cause” shall be determined by a majority of the Board (excluding Employee
if a Board member) and shall mean: 
 (i) The willful failure, disregard or refusal by Employee to perform his duties as an employee of the
Company; 
 (ii) Any willful, intentional or grossly negligent act by Employee having the effect of injuring, in a material way (whether
financial or otherwise), the business or reputation of the Company or any of its affiliates; 
 (iii) Willful misconduct by Employee in
respect of the duties or obligations of Employee, including, without limitation, insubordination with respect to lawful directions received by Employee from the Company or the Board; 

(iv) Employee’s conviction of any felony (including entry of a nolo contendere or no contest plea); 

(v) The determination by the Company, after a reasonable and good-faith investigation by the Company following a written allegation by
another employee of the Company, that Employee personally engaged in some form of discrimination, harassment or retaliatory conduct prohibited by law (including, without limitation, discrimination based on race, color, religion, sex, national
origin, age, disability or other status protected by law); 
 (vi) Any violation of the Company’s Code of Conduct (as it may be
modified from time to time) or Insider Trading Policy or other similar policies that injures, or in the determination of the Board, has the potential to injure in a material way (whether financial or otherwise), the business or reputation of the
Company or any of its affiliates that, if capable of being cured, is not cured by Employee within thirty (30) days after notice thereof is given to Employee by the Company; 

(vii) Any misappropriation or embezzlement of the property of the Company or its affiliates (whether or not a misdemeanor or felony); 

(viii) Breach by Employee of the Confidentiality and Assignment of Inventions Agreement entered into by and between Employee and the Company
prior to the date hereof (the “Confidentiality and Assignment of Inventions Agreement”), that, if capable of being cured, is not cured by Employee within thirty (30) days after notice thereof is given to Employee by the
Company; and 
 (ix) Breach by Employee of any provision of this Agreement other than those contained in the Confidentiality and Assignment
of Inventions Agreement, that, if capable of being cured, is not cured by Employee within thirty (30) days after notice thereof is given to Employee by the Company. 

(f) The “Code” means the Internal Revenue Code of 1986, as amended. 

  
 2 

 (g) “Good Reason” shall mean any of the following: (i) the assignment to
Employee of duties materially inconsistent with Employee’s position, duties, responsibilities, titles or offices as described herein; (ii) material reduction by the Company of Employee’s duties and responsibilities; (iii) any
reduction or series of reductions in excess of ten percent (10%) by the Company of Employee’s compensation or benefits payable hereunder (it being understood that a reduction of benefits applicable to all employees of the Company,
including Employee, shall not be deemed a reduction of Employee’s compensation package for purposes of this definition); or (iv) a change of more than thirty-five (35) miles in the geographic location at which Employee must perform
services for the Company. Notwithstanding the foregoing, Employee shall not have Good Reason for termination unless Employee gives written notice of termination for Good Reason within thirty (30) days after the event giving rise to Good Reason
occurs, and the Company does not correct the action or failure to act that constitutes the grounds for Good Reason, as set forth in Employee’s notice of termination, within thirty (30) days after the date on which Employee gives written
notice of termination. 
 (h) “Disability” shall mean that Employee has been unable to substantially perform the essential
job duties of his position hereunder with or without a reasonable accommodation for ninety (90) or more consecutive days, or more than one hundred twenty (120) days in any consecutive twelve (12) month period, by reason of any
physical or mental illness or injury, as determined by the Board in its reasonable discretion. 
 (i) The “Term” of this
Agreement shall mean an initial period of five (5) years following the Effective Date, plus successive one (1) year renewal periods thereafter so long as the Company does not provide Employee with written notice of its intention not to
renew this Agreement at least ninety (90) days prior to the expiration of the initial five (5) year period or any additional one (1) year renewal period. 

(j) “Termination Date” shall mean the effective date of Employee’s termination of employment with the Company. 

(k) “Effective Release” is defined as a general release of claims in favor of the Company in a form reasonably acceptable to
the Company’s counsel that is executed by Employee after the Termination Date and within any consideration period required by applicable law and that is not revoked by Employee within any legally prescribed revocation period. 

2. Compensation upon Termination. 

(a) Upon termination of employment by either party for any reason whatsoever, Employee shall be entitled to continue to receive his Base
Salary, minus applicable withholdings required by law or authorized by Employee, and reimbursement of any accrued, unpaid and appropriately documented business expenses through the Termination Date. 

(b) In addition, if during the Term of this Agreement, Employee’s employment with the Company is terminated within twelve
(12) months after a Change in Control, either by the Company without Cause (and other than due to death or Disability) or by 

  
 3 

 
Employee for Good Reason, and (1) such termination results in Employee incurring a “separation from service” as defined under Treasury Regulation 1.409A-1(h); (2) Employee has
not breached this Agreement or the Confidentiality and Assignment of Inventions Agreement; and (3) conditioned upon Employee’s execution of an Effective Release, Employee shall be entitled to, in lieu of any other separation payment or
severance benefit: 
 (i) Payment of an amount equal to twelve (12) months of his Base Salary, minus applicable withholdings required
by law or authorized by Employee, to be paid pursuant to the Company’s standard payroll practices and procedures, beginning on the Company’s next regular pay day occurring sixty (60) days following the Termination Date; 

(ii) Payment in a lump sum, on the Company’s next regular pay day occurring sixty (60) days following the Termination Date, of a
pro rata bonus based upon Employee’s target bonus amount for the year in which the Termination Date occurs, pro-rated for the portion of the calendar year through the Termination Date; 

(iii) Accelerated vesting of all outstanding and unvested stock options and other equity in the Company held by Employee, which shall become
immediately and fully exercisable, subject to all other terms of the applicable equity plan and award agreement; and 
 (iv) Conditioned on
Employee’s proper and timely election to continue his health insurance benefits under COBRA after the Termination Date, reimbursement of Employee’s applicable COBRA premiums for the lesser of twelve (12) months following the
Termination Date or until Employee becomes eligible for insurance benefits from another employer, provided, however, that the Company has the right to terminate such payment of COBRA premium reimbursement to Employee and instead pay Employee a lump
sum amount equal to the applicable COBRA premium multiplied by the number of months remaining in the specified period if the Company determines in its discretion that continued payment of the COBRA premiums is or may be discriminatory under
Section 105(h) of the Internal Revenue Code. 
 (c) Upon termination of Employee’s employment (i) as a result of
Employee’s death or Disability, (ii) by the Company for Cause, (iii) by Employee without Good Reason, or (iv) for any reason following the Term of this Agreement, Employee shall not be entitled to additional compensation under
this Agreement beyond that accrued as of the Termination Date. 
 3. Section 409A. 

(a) The parties hereby acknowledge and agree that all benefits or payments provided by the Company to Employee pursuant to this Agreement are
intended either to be exempt from the provisions of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, “Section 409A”), or to be in compliance with
Section 409A, and the Agreement shall be interpreted to the greatest extent possible to be so exempt or in compliance. If there is an ambiguity in the language of the Agreement, or if Section 409A guidance indicates that a change to the
Agreement is required or desirable to achieve exemption or compliance with Section 409A, Company and Employee agree to attempt to renegotiate in good faith to clarify the ambiguity or make such change. 

  
 4 

 (b) If any severance or other payments that are required by the Agreement are to be paid in a
series of installment payments, each individual payment in the series shall be considered a separate payment for purposes of Section 409A. 

(c) If any severance compensation or other benefit provided to Employee pursuant to this Agreement that constitutes “nonqualified
deferred compensation” within the meaning of Section 409A is considered to be paid on account of “separation from service” within the meaning of Section 409A, and Employee is a “specified employee” within the
meaning of Section 409A, no payments of any of such severance or other benefit shall made for six (6) months plus one (1) day after the Separation Date (the “New Payment Date”). The aggregate of any such payments that
would have otherwise been paid during the period between the Separation Date and the New Payment Date shall be paid to the Employee in a lump sum on the New Payment Date. 

4. Excess Parachute Payments. If any payments or benefits received or to be received by Employee pursuant to this Agreement in
connection with or contingent on a change in ownership or control are deemed to be an “excess parachute payment” within the meaning of Section 280G of the Code (“Excess Parachute Payment”), and if the Company has no
publicly traded stock, the Company will use commercially reasonable efforts to obtain “shareholder approval” within the meaning of Section 280G(b)(5) of the Code of such payments or benefits in order to exempt such payments or
benefits from being considered an Excess Parachute Payment. If, notwithstanding the foregoing, such payments or benefits still would be considered to result in an Excess Parachute Payment, then, at Company’s election, such payments under this
Agreement shall either be paid in full or reduced to the extent necessary to avoid being considered an Excess Parachute Payment, based upon Company’s determination, in its sole discretion, as to which alternative results in the better tax
consequences for the Employee. 
 5. Employment At Will. Nothing herein is meant to alter the “at will” status of
Employee’s employment with the Company. Subject to the provisions of Section 2 above regarding payments in connection with a termination following a Change in Control, Employee’s employment with the Company may be terminated at any
time, for any or no cause or reason, by either Employee or by the Company. 
 6. Non-Competition, Non-Solicitation and
Non-Disparagement. 
 (a) While Employee is employed by the Company and for a period of twelve (12) months after the termination or
cessation of such employment by either party for any reason whatsoever, Employee will not, directly on Employee’s own behalf or indirectly for or in conjunction with others: 

(i) Within the Restricted Territory (as defined in subsection (b) below), engage in any business or enterprise (whether as owner,
partner, officer, director, employee, consultant, investor, lender or otherwise) that develops, manufactures, markets, licenses or sells any pharmaceutical antibiotic products that compete with the products being

  
 5 

 
sold or developed by the Company at the time of Employee’s termination (collectively, the “Competitive Products”) in any management or executive role in which Employee would
perform duties that are the same or substantially similar to those duties actually performed by Employee for the Company in the twelve (12) months immediately prior to the termination of Employee’s employment, or in any position where
Employee or such business or enterprise would benefit from Employee’s use or disclosure of the Company’s Proprietary Information as defined in the Confidentiality and Assignment of Inventions Agreement; 

(ii) Within the Restricted Territory, solicit or accept employment or be retained by an individual or entity who, at any time during the term
of this Agreement, was an agent, client, licensee, or customer of the Company, where Employee would have any management or executive role or be in any position (whether as an employee, contractor or consultant) in which Employee would perform duties
that are the same or substantially similar to those duties actually performed by Employee for the Company in the twelve (12) months immediately prior to the termination of Employee’s employment or in any position where Employee or such
individual or entity would benefit from Employee’s use or disclosure of the Company’s Proprietary Information as defined in the Confidentiality and Assignment of Inventions Agreement; 

(iii) Within the Restricted Territory, become financially interested in an enterprise that is engaged, as a substantial part of its
operations, in developing, manufacturing, marketing, licensing or selling the Competitive Products; provided, however, that nothing in this Agreement shall be construed to prevent Employee from owning less than five percent (5%) of the
outstanding voting securities of any entity whose voting securities are listed on a national securities exchange; 
 (iv) Solicit or accept
the business of any customer of the Company whom Employee solicited or serviced for the Company during the last twelve (12) months of Employee’s employment with the Company for the purpose of selling or providing Competitive Products to
such customer; and/or 
 (v) Solicit, induce or encourage any employee, consultant, or independent contractor of the Company to terminate
his or her employment or contracting relationship with the Company. 
 (b) For purposes of this Agreement, the “Restricted
Territory” means North America; but if such territory is determined to be overly broad, then the United States; and, if such territory is also determined to be overly broad, then each state or province in North America in which the Company
engages in material business activities or sells or licenses its products. Provided, however, that it shall not be a violation of this Section 6 for Employee to work outside of the Restricted Territory for any business or enterprise that
develops, manufactures, markets, licenses or sells Competitive Products, so long as that business or enterprise does not manufacture, market, license or sell any Competitive Products that compete with the Company’s products within the
Restricted Territory. 
 (c) During Employee’s employment with the Company and at all times

  
 6 

 
thereafter, the Company and Employee each further agree that neither party shall directly or indirectly disparage or defame the name or reputation of the other party or any of its affiliates,
including but not limited to any officer, director, employee or shareholder of the Company or any of its affiliates. 
 (d) In the event of
a breach or threatened breach of this Section 6 by Employee, then, in addition to any other rights which the Company may have, (i) the Company will have the right to immediately terminate any remaining payment obligations to Employee
pursuant to Sections 2(b)(i), 2(b)(ii), and 2(b)(iv) above without any further obligation to Employee, and Employee will immediately repay to the Company any amounts previously paid to Employee pursuant to Section 2(b)(i), 2(b)(ii), and
2(b)(iv) above; (ii) the Company will be entitled to injunctive relief to enforce this Section 6 (and notwithstanding anything set forth in Section 7(b) below, the Company may seek injunctive relief in any court of competent
jurisdiction without waiving the right to arbitration under Section 7(b)); and (iii) the Company will have the right to require Employee to account for and pay over to the Company all compensation, profits, monies, accruals, increments and
other benefits (collectively, the “Benefits”) derived or received by Employee as a result of any transaction constituting a breach of any of the provisions of Section 6, and Employee hereby agrees to account for and pay over
such Benefits to the Company. Notwithstanding the foregoing, the sole remedy available to the Company with respect to a breach by Employee of (a)(i), (a)(iii) or (a)(iv) above that relates to Competitive Products other than a product or products in
the fusidane or macrolide classes of products shall be termination effective as of the breach of any remaining payment obligations pursuant to Section 2(b) of this Agreement. 

(e) Each of the rights and remedies enumerated in Section 6(d) shall be independent of the others and shall be in addition to, and not
in lieu of, any other rights and remedies available to the Company at law or in equity. If any of the covenants contained in this Section 6, or any part of any of them, is hereafter construed or adjudicated to be invalid or unenforceable, the
same shall not affect the remainder of the covenant or covenants or rights or remedies which shall be given full effect without regard to the invalid portions. If any of the covenants contained in this Section 6 is held to be invalid or
unenforceable because of the duration of such provision or the area covered thereby, the parties agree that the court or arbitrator making such determination shall have the power to reduce the duration and/or area of such provision and in its
reduced form such provision shall then be enforceable. No such holding of invalidity or unenforceability in one jurisdiction shall bar or in any way affect the Company’s right to the relief provided in this Section 6 or otherwise in the
courts of any other state or jurisdiction within the geographical scope of such covenants as to breaches of such covenants in such other respective states or jurisdictions, such covenants being, for this purpose, severable into diverse and
independent covenants. 
 (f) The provisions of this Section 6 will survive any termination of this Agreement and the termination of
Employee’s employment with the Company. 
 7. Miscellaneous. 

(a) This Agreement is governed by and will be construed and interpreted in accordance with the laws of the State of North Carolina, without
reference to its conflict of laws principles. 

  
 7 

 (b) Any dispute arising out of, or relating to, this Agreement or the breach thereof, or
regarding the interpretation thereof, shall be finally settled by binding arbitration conducted in Raleigh, North Carolina and administered by the American Arbitration Association (“AAA”) pursuant to its then-current Employment
Arbitration Rules and Mediation Procedures (available at www.adr.org). The arbitration shall be conducted by a single experienced arbitrator or retired judge, to be chosen via the AAA’s selection procedures. The arbitrator’s award shall be
final and binding. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator may award monetary damages and, in the arbitrator’s discretion, attorneys’ fees and/or costs to
the prevailing party if allowed by statute. The arbitrator may not award punitive damages or any other type of exemplary damages unless such damages are specifically authorized by statute. Any filing fees and the fees and costs of the arbitrator
shall be paid equally by the Company and Employee. Each party shall pay the fees of his or its attorneys, the expenses of his or its witnesses, and any other expenses that party incurs in connection with the arbitration. For the purpose of any
judicial proceeding to enforce such award or incidental to such arbitration or to compel arbitration, the parties hereby submit to the sole and exclusive jurisdiction of the state or federal courts sitting in Orange County, North Carolina, and agree
that service of process in such arbitration or court proceedings shall be satisfactorily made upon it or him if sent by registered mail addressed to it or him at the address referred to in Section 7(g) of this Agreement. 

(c) This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives,
successors and assigns. 
 (d) This Agreement, and Employee’s rights and obligations hereunder, may not be assigned by Employee. The
Company may assign its rights, together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets, but no such assignment shall release the Company of its
obligations hereunder. 
 (e) This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written
agreement signed by the parties hereto. 
 (f) The failure of either party to insist upon the strict performance of any of the terms,
conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of
this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party. 

(g) All notices, requests, consents and other communications, required or permitted to be given hereunder, shall be in writing and shall be
delivered personally or by an overnight courier service or sent by registered or certified mail, postage prepaid, return receipt requested, to the parties at the addresses set forth on the first page of this Agreement, and shall be deemed given when
so delivered personally or by overnight courier, or, if mailed, five days after the date of deposit in the United States mail. Either party may designate another address, for receipt of notices hereunder by giving notice to the other party in
accordance with this paragraph (g). 

  
 8 

 (h) This Agreement sets forth the entire agreement and understanding of the parties relating to
the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. No representation, promise or inducement has been made by either party that is not embodied in
this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth. 
 (i)
As used in this Agreement, an “affiliate” of a specified person or entity shall mean and include any person or entity controlling, controlled by or under common control with the specified person or entity. 

(j) The section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of
this Agreement. 
 (k) This Agreement may be executed in any number of counterparts, each of which shall constitute an original, but all of
which together shall constitute one and the same instrument. 
 [Remainder of Page Intentionally Left Blank] 

  
 9 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written. 
  

			
	CEMPRA, INC.
		
	By:	 	 /s/ Prabhavathi Fernandes, Ph.D.

	Name:	 	Prabhavathi Fernandes, Ph.D.
	Title:	 	President and CEO

  

			
	EMPLOYEE
		
	By:	 	 /s/ David W. Oldach, M.D.

	Name:	 	David W. Oldach, M.D.

 [Signature Page to Change in Control Severance Agreement – D. Oldach]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]